undamentalytics Newsletter
Sign in

Haoxi Health Technology Ltd (HAO) stock

Add to watchlist

Add holding +

NASDAQ: HAO Nasdaq Health Care Services

C+ Fundamentals grade

Haoxi Health Technology Ltd is a US-listed company in the health care services industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: share count (0m) is 0.07x the market-data count (0m).

Price vs value

Under review: share count (0m) is 0.07x the market-data count (0m). We'll show the comparison once resolved.

Haoxi Health Technology Ltd valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades

Value diary

Our note on each quarter Haoxi Health Technology files

Where Haoxi Health Technology stands after its latest Filing

Revenue for the twelve months was $55m, up 67.1% on a year earlier, against a decline of 32.4% a quarter earlier. That growth ranks 1 of 41 among the health care services companies we cover. Free-cash-flow margin fell to -5.2% from -4.2% a year earlier. Operating margin narrowed to -17.6% from 1.7%. The diluted share count is up 2536.8% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 3 financial-health checks.

Our model value for Haoxi Health Technology is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Haoxi Health Technology Ltd's trailing-twelve-month revenue grew 67.1% year on year, with a free-cash-flow margin of -5.2%. Where it stands out: revenue growth of 67.1% ranks 1 of 41 health care services companies we cover. Where it lags: change in share count of 2536.8% ranks 39 of 39 health care services companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 67.1% (+99.5pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 67.1% over the last 12 months, against a median of 7.3% for health care services companies we cover.
  • Growth speeding up. The growth rate is 99.5 points higher than a quarter earlier.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Loss-making. Operating margin is -17.6%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 11.5 points on a year ago.
  • Burning cash. Free cash flow was -5.2% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 2536.8% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 136% and a beta of 0.7 against the S&P 500.
  • Below peers: gross margin. Gross margin of 1.1% ranks 26 of 27 health care services companies we cover (median 29.0%).

Price chart

  • 1 day+2.1%
  • 1 week0.0%
  • 1 month-27.4%
  • This year-98.6%
  • 1 year-98.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$54.8M
Operating margin
-17.6%
Net margin
-17.4%
EPS (TTM, diluted)
$-386.40

Growth

Revenue growth
+67.1%
Change in growth rate
+99.5 pts
Share count change
+2536.8%

Cash

Free cash flow (TTM)
-$2.9M
FCF margin
-5.2%
Stock pay % of revenue
0.2%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for HAO from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Haoxi Health Technology Ltd valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: share count (0m) is 0.07x the market-data count (0m): held for review.

Valuation multiples over time Market data may be delayed

At fiscal year end 202420252026
Share price$13670.40$166.40$20.60
Market value$13m$155750$508408
+ Net debt (− = net cash)−$5m−$7m−$11m
Enterprise value$8m−$7m−$10m
Multiples
Price / sales 0.3x0.0x0.0x
Price / earnings 10.1x0.0x—
Price / free cash flow ———
EV / EBITDA 4.4x——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Haoxi Health Technology Ltd: too few analysts cover it.

Positioning

Short interest
9.1%
of tradable shares
Days to cover
0.31
at average volume
Short interest, 1 month
+41%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
0.0%
of shares
Employees
28
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20252026 to date
Return
HAO−64%−99%
Industry peers (median)−6%+15%
S&P 500+18%+11%
Months that ended higher
HAO33%27%
S&P 50075%46%
Largest fall from a high during the year
HAO−77%−99%
S&P 500−19%−9%

Worst fall since January 26, 2024: 100% from May 2, 2024 to October 27, 2026. Getting back needed a 1425500% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.60 – $204.80
From 52-week high
−99.0%
vs 50-day average
−26.1%
vs 200-day average
−97.0%
Volatility (1 year)
136%
Beta vs S&P 500
0.72

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Haoxi Health Technology Ltd in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Haoxi Health Technology Ltd
$0 $20M $40M $60M FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 FY26 Q4 Revenue (TTM), FY22 Q4: $16.2M Revenue (TTM), FY23 Q4: $28.2M Revenue (TTM), FY24 Q4: $48.5M Revenue (TTM), FY25 Q4: $32.8M Revenue (TTM), FY26 Q4: $54.8M $54.8M

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue (TTM)
FY22 Q4 $16.2M
FY23 Q4 $28.2M
FY24 Q4 $48.5M
FY25 Q4 $32.8M
FY26 Q4 $54.8M
Revenue growth, TTM YoY Haoxi Health Technology Ltd
-50% 0% 50% 100% FY23 Q4 FY24 Q4 FY25 Q4 FY26 Q4 Revenue growth, TTM YoY, FY23 Q4: 74.7% Revenue growth, TTM YoY, FY24 Q4: 71.9% Revenue growth, TTM YoY, FY25 Q4: -32.4% Revenue growth, TTM YoY, FY26 Q4: 67.1% 67.1%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 74.7%
FY24 Q4 71.9%
FY25 Q4 -32.4%
FY26 Q4 67.1%
Operating margin (TTM) Haoxi Health Technology Ltd
-20% -10% 0% 10% FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 FY26 Q4 Operating margin (TTM), FY22 Q4: 1.7% Operating margin (TTM), FY23 Q4: 4.2% Operating margin (TTM), FY24 Q4: 3.5% Operating margin (TTM), FY25 Q4: -6.1% Operating margin (TTM), FY26 Q4: -17.6% -17.6%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period Operating margin (TTM)
FY22 Q4 1.7%
FY23 Q4 4.2%
FY24 Q4 3.5%
FY25 Q4 -6.1%
FY26 Q4 -17.6%
FCF margin (TTM) Haoxi Health Technology Ltd
-15% -10% -5% 0% FY22 Q4 FY23 Q4 FY24 Q4 FY25 Q4 FY26 Q4 FCF margin (TTM), FY22 Q4: -4.2% FCF margin (TTM), FY23 Q4: -3.3% FCF margin (TTM), FY24 Q4: -1.7% FCF margin (TTM), FY25 Q4: -11.1% FCF margin (TTM), FY26 Q4: -5.2% -5.2%

Source: SEC EDGAR filings. Retrieved Invalid Date.

View chart data
Period FCF margin (TTM)
FY22 Q4 -4.2%
FY23 Q4 -3.3%
FY24 Q4 -1.7%
FY25 Q4 -11.1%
FY26 Q4 -5.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Jun 2022 2023 Jun 2023 2024 Jun 2024 2025 Jun 2025 2026 Jun 2026
Income
Revenue 16 28 49 33 55
Gross profit 1 2 3 1 1
EBITDA 0 1 2 −2 −9
Operating income 0 1 2 −2 −10
Net income 0 1 1 4 −10
Diluted EPS $0.01 $0.43 $1350.77 $3385.53 −$386.40
Growth (year on year)
Revenue — +74.7% +71.9% −32.4% +67.1%
EBITDA — — +43.5% −198.7% —
Operating income — — +43.6% −216.5% —
Net income — — +33.2% +200.1% −346.0%
Diluted EPS — — +>999% +150.6% −111.4%
Margins
Gross margin 4.0% 7.3% 5.7% 2.8% 1.1%
EBITDA margin 1.7% 4.3% 3.6% −5.2% −17.1%
Operating margin 1.7% 4.2% 3.5% −6.1% −17.6%
Net margin 1.5% 3.4% 2.7% 11.8% −17.4%
Free-cash-flow margin −4.2% −3.3% −1.7% −10.2% −4.7%
Cash flow
Cash from operations −1 −1 −1 −3 −3
Capital spending 0 0 0 0 0
Free cash flow −1 −1 −1 −3 −3
Stock-based pay 0 2 — 0 —
Free cash flow after stock pay −1 −3 — −3 —
Balance sheet
Cash 0 1 7 9 11
Total debt 0 1 1 2 —
Net debt (negative = net cash) −0 −0 −5 −7 −11
Diluted shares 50m 2m — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $22m
Short-term assets $17mLonger-term assets $5m
What it owes, and who funded it · $22m
Short-term liabilities $4mLonger-term liabilities $0mShareholders' equity $18m
  • Short-term assets cover short-term liabilities $17m of assets due within a year against $4m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $17m short-term assets against $0 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$10m against $52,446 of interest.

From Haoxi Health Technology Ltd's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+2536.8%
year over year
R&D spending
0.2%
of revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated HAO CCEL AMS RDGT NRC AIRS Median
Revenue, last 12 months $55m $31m $30m $132m $140m $151m $1.2bn
Revenue growth, last 12 months 67.1% −2.0% 4.0% 10.2% −0.2% −8.7% 7.3%
Revenue growth, 3-year average — −0.1% 14.3% — −1.9% −5.9% 11.3%
Revenue growth, latest quarter — −0.0% 19.2% — 4.0% −2.5% 8.5%
Gross margin 1.1% 78.5% 17.1% 3.6% — — 27.9%
Operating margin −17.6% 0.6% −11.8% −1.4% 10.5% −8.4% 2.3%
Operating margin, 3-year average — −8.4% −8.5% — 19.1% −3.0% 2.3%
Net margin −17.4% −6.2% −5.8% −0.9% 4.0% −7.8% 1.2%
Cash from operations / revenue −4.7% 15.8% 17.6% −1.1% 21.1% 0.8% 6.1%
Free-cash-flow margin −5.2% 14.9% 11.6% −1.1% 15.5% 0.5% 5.1%
Free-cash-flow margin, 3-year average — 14.7% −14.8% — 12.5% 0.6% 3.6%
Stock pay / revenue 0.2% 1.1% 1.3% 8.6% 8.4% 0.8% 1.1%
Change in share count >999% −1.4% 0.4% 96.6% −5.2% 13.3% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth 67.1% 7.3% 1 of 41
Change in growth rate Growth +99.5pp +1.1pp 1 of 41
Gross margin Profitability 1.1% 29.0% 26 of 27
Operating margin Profitability -17.6% 2.6% 33 of 40
Net margin Profitability -17.4% 1.2% 35 of 41
Free-cash-flow margin Cash generation -5.2% 5.1% 33 of 40
Stock pay as % of revenue Cash generation 0.2% 0.9% 2 of 35
Long-term debt as % of assets Balance sheet 1.4% 27.7% 3 of 31
Change in share count Balance sheet 2536.8% 0.4% 39 of 39

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Insider trading activity

Full insider history and chart
Insider purchases History → $800,000 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $800,000 net buying
Insider Date Trade Shares Price Value
Fan Zhen CEO & Chairman May 19, 2026 Buy 40,000,000 $0.02 $800,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Haoxi Health Technology Ltd was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Haoxi Health Technology Ltd in brief

What does Haoxi Health Technology Ltd do?
Haoxi Health Technology Ltd is a US-listed company in the health care services industry. Its financial year ends in June.
What is Haoxi Health Technology Ltd's stock ticker?
Haoxi Health Technology Ltd trades under the ticker HAO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Haoxi Health Technology Ltd's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Haoxi Health Technology Ltd reported revenue of $54.8M, 67.1% higher than a year earlier, according to its SEC filings.
What is Haoxi Health Technology Ltd's free cash flow?
Haoxi Health Technology Ltd's free-cash-flow margin is -5.2% of revenue over the trailing twelve months, ranking 33 of the 40 health care services companies we cover.
What is Haoxi Health Technology Ltd's market cap?
On June 30, 2026, Haoxi Health Technology Ltd's market capitalisation was about $508,408 and net debt of -$10.9M. Market figures come from third-party market data and may be delayed.
Who are Haoxi Health Technology Ltd's competitors?
In our Health Care Services peer group, the companies closest to Haoxi Health Technology Ltd are Cryo Cell International Inc, American Shared Hospital Services, Ridgetech Inc., NRC Health and Airsculpt Technologies, Inc. The side-by-side comparison below sets their revenue, margins and growth against Haoxi Health Technology Ltd's.
Are insiders buying or selling Haoxi Health Technology Ltd stock?
Over the last 12 months, Haoxi Health Technology Ltd's directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.